Fab-PEG-Fab as a potential antibody mimetic

Bioconjugate Chemistry

Volumn 24, Issue 11, 2013, Pages 1870-1882

  Khalili, Hanieh ^a,b   Godwin, Antony ^c   Choi, Ji Won ^c   Lever, Rebecca ^a   Khaw, Peng T ^b   Brocchini, Steve ^a,b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c Antitope Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIBODIES; COVALENT BONDS; DISSOCIATION; SULFUR COMPOUNDS;

BEVACIZUMAB; CONJUGATED PROTEINS; DISSOCIATION RATES; DISULPHIDE BONDS; FLEXIBLE MOLECULES; MIMETICS; PEGYLATED; SITE-SPECIFIC; SOLUTION STRUCTURES; SPECIFIC CONJUGATIONS;

MOLECULES;

ANGIOGENESIS INHIBITOR; ANTIBODY CONJUGATE; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; MACROGOL; PEGYLATED FAB BEVACIZUMAB; PEGYLATED FAB RANIBIZUMAB; PEGYLATED FAB TRASTUZUMAB; RANIBIZUMAB; RECOMBINANT VASCULOTROPIN; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN ANTIBODY;

ALKYLATION; ANTIANGIOGENIC ACTIVITY; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ARTICLE; CONTROLLED STUDY; DISULFIDE BOND; DRUG CONJUGATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT SCATTERING; MOLECULAR MIMICRY; MOLECULAR SIZE; PROTEIN DEGRADATION;

ANTIGEN-ANTIBODY REACTIONS; BIOMIMETIC MATERIALS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; MODELS, MOLECULAR; MOLECULAR STRUCTURE; POLYETHYLENE GLYCOLS;

EID: 84888580381     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc400246z     Document Type: Article

References (108)

1. Paul, W. (2012) Fundamental Immunology, pp 140-142, Lippincott Williams and Wilkins.
2. Harris, L. J., Larson, S. B., Skaletsky, E., and Mcpherson, A. (1998) Comparison of the conformations of two intact monoclonal antibodies with hinges Immunol. Rev. 163, 35-43
3. Wang, X., Kumar, S., and Singh, S. (2011) Disulfide scrambling in IgG2monoclonal antibodies: Insights from molecular dynamics simulations Pharm. Res. 28, 3128-3143
4. Khalili, H., Godwin, A., Choi, J., Lever, R., and Brocchini, S. (2012) Comparative binding of disulfide-bridged PEG-Fabs Bioconjugate Chem. 23 (11) 2262-2277
5. Balan, S., Choi, J. W., Godwin, A., Teo, I., Laborde, C. M., Heidelberger, S., Zloh, M., Shaunak, S., and Brocchini, S. (2007) Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge Bioconjugate Chem. 18 (1) 61-76
6. Shaunak, S., Godwin, A., Choi, J. W., Balan, S., Pedone, E., Vijayarangam, D., Heidelberger, S., Teo, I., Zloh, M., and Brocchini, S. (2006) Site-specific PEGylation of native disulfide bonds in therapeutic proteins Nat. Chem. Biol. 312-313
7. Cong, Y., Pawlisz, E., Bryant, P., Balan, S., Laurine, E., Tommasi, R., Singh, R., Dubey, S., Peciak, K., Bird, M., Sivasankar, A., Swierkosz, J., Muroni, M., Heidelberger, S., Farys, M., Khayrzad, F., Edwards, J., Badescu, G., Hodgson, I., Heise, C., Somavarapu, S., Liddell, J., Powell, K., Zloh, M., Choi, J.-W., Godwin, A., and Brocchini, S. (2012) Site-specific PEGylation at histidine tags Bioconjugate Chem. 23 (2) 248-263
8. Holliger, P. and Hudson, P. J. (2005) Engineered antibody fragments and the rise of single domains Nat. Biotechnol. 23 (9) 1126-1136
9. Labrijn, A. F., Aalberse, R. C., and Schuurman, J. (2008) When binding is enough: Nonactivating antibody formats Curr. Opin. Immunol. 20, 479-485
10. Nelson, A. L. and Reichert, J. M. (2009) Development trends for therapeutic antibody fragments Nat. Biotechnol. 27 (4) 1-7
11. Nelson, A. L. (2010) Antibody fragments; Hope and hype mAbs 2 (1) 77-83
12. Vlasak, J. and Ionescu, R. (2011) Fragmentation of monoclonal antibodies mAbs 3 (3) 253-263
13. Yan, B., Boyd, D., Kaschak, T., Tsukuda, J., Shen, A., Lin, Y., Chung, S., Gupta, P., Kamath, A., Wong, A., Vernes, J.-M., Meng, G. Y., Totpal, K., Schaefer, G., Jiang, G., Nogal, B., Emery, C., Vanderlaan, M., Carter, P., Harris, R., and Amanullah, A. (2012) Engineering upper hinge improves stability and effector function of a human IgG1 J. Biol. Chem. 287 (8) 5891-5897
14. Ngadi, N., Abrahamson, J., Fee, C., and Morison, K. (2009) Are PEG molecules a universal protein repellent? Int. J. Biol. Life Sci. 1 (3) 116-120
15. Rajan, R. S., Li, T., Aras, M., Sloey, C., Sutherland, W., Arai, H., Briddell, R., Kinstler, O., Lueras, A. M. K., Zhang, Y., Yeghnazar, H., Treuheit, M., and Brems, D. N. (2006) Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study Protein Sci. 15 (5) 1063-1075
16. Webster, R., Didier, E., Harris, P., Siegel, N., Stadler, J., Tilbury, L., and Smith, D. (2007) PEGylated proteins:evaluation of their safety in the absence of definitive metabolism studies Drug Metab. Dispos. 35 (1) 9-16
17. Foster, G. R. (2010) PEGylated interferons for the treatment of chronic hepatitis C: Pharmacological and clinical differences between PEGinterferon-2a and PEGinterferon-2b Drugs 70 (2) 147-165
18. Yang, B. (2006) in Pharmacokinetics and Pharmacodynamics of Biotech Drugs (Meibohm, B., Ed.) pp 373-393, Wiley-VCH, Weinheim.
19. Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., and Adamis, A. P. (2006) PEGaptanib, a targeted anti-VEGF aptamer for ocular vascular disease Nat. Rev. Drug Discovery 5 (2) 123-132
20. Meyer, C. H. and Holz, F. G. (2011) Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: Ranibizumab and bevacizumab Eye 25 (6) 661-672
21. Niu, N., Zhang, J., Sun, Y., Wang, S., Sun, Y., Korteweg, C., Gao, W., and Gu, J. (2010) Expression and distribution of immunoglobulin G and its receptors in an immune privileged site: The eye Cell. Mol. Life Sci. 68 (14) 2481-2492
22. Van Bilsen, K., Van Hagen, P. M., Bastiaans, J., Van Meurs, J. C., Missotten, T., Kuijpers, R. W., Hooijkaas, H., Dingjan, G. M., Baarsma, G. S., and Dik, W. A. (2011) The neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumour necrosis factor-alpha Brit. J. Ophthalmol. 95 (6) 864-868
23. Heiduschka, P., Fietz, H., Hofmeister, S., Schultheiss, S., Mack, A. F., Peters, S., Ziemssen, F., Niggemann, B., Julien, S., Bartz-Schmidt, K. U., and Schraermeyer, U. (2007) Penetration of Bevacizumab through the Retina after Intravitreal Injection in the Monkey Invest. Ophthalmol. Vis. Sci. 48 (6) 2814-2823
24. Kim, H., Robinson, S., and Csaky, K. (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye Mol. Vis. 15, 2803-2812
25. Kim, H., Fariss, R. N., Zhang, C., Robinson, S. B., Thill, M., and Csaky, K. G. (2008) Mapping of the neonatal Fc receptor in the rodent eye Invest. Ophthalmol. Vis. Sci. 49 (5) 2025-2029
26. Bakri, S. J., Snyder, M., Reid, J., Pulido, J., Ezzat, M., and Singh, R. (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis) Ophthalmology 114 (12) 2179-2182
27. Li, J., Gupta, M., Jin, D., Xin, Y., Visich, J., and Allison, D. E. (2012) Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon Cancer Chemother. Pharmacol. 71 (3) 575-580
28. Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., and Adelman, D. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J. Clin. Oncol. 19 (3) 843-850
29. Meyer, C. H., Krohne, T. U., and Holz, F. G. (2011) Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans Retina (Philadelphia, Pa) 31 (9) 1877-1884
30. Krohne, T. U., Liu, Z., Holz, F. G., and Meyer, C. H. (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans Am. J. Ophthal. 154 (4) 682-686.e2
31. Xu, L., Lu, T., Tuomi, L., Jumbe, N., Lu, J., Eppler, S., Kuebler, P., Damico-Beyer, L. A., and Joshi, A. (2013) Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: A population approach Invest. Ophthalmol. Vis. Sci. 54 (3) 1616-1624
32. Brocchini, S., Balan, S., Godwin, A., Choi, J. W., Zloh, M., and Shaunaik, S. (2006) PEGylation of native disulfide bonds in proteins Nat. Protoc. 1 (5) 2241-2252
33. Scollard, D. A., Chan, C., Holloway, C. M. B., and Reilly, R. M. (2011) A kit to prepare 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer Nucl. Med. Biol. 38 (1) 129-136
34. Demeule, B., Palais, C., Machaidze, G., Gurny, R., and Arvinte, T. (2009) New methods allowing the detection of protein aggregates, A case study on trastuzumab mAbs 1 (2) 142-150
35. Barbas, C. F., Crowe, J. E., Cababa, J. R. D., Suzanne, T. M. J., Zebedeei, L., Murphy, B. R., Chanock, R. M., and Burton, D. R. (1992) Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralizeinfectivity Proc. Natl. Acad. Sci. U.S.A. 89, 10164-10168
36. Minor, L. K. (2006) in Drug Discovery Series (Carmen, A., Ed.) p 423, CRC Press, Taylor & Francis Group.
37. Nikolayenko, I. V., Galkin, O. Y., Grabchenko, N. I., and Spivak, M. Y. (2005) Preparation of highly purified human IgG, IgM, and IgA for immunization and immunoanalysis Ukrainica Bioorganica Acta (Ukr. Biokhim. Zh.) 3-11
38. Thermo Scientific (2008) Extinction Coefficients guideline:TR0006.3, pp 1-4.
39. Kang, J. S., Deluca, P. P., and Lee, K. C. (2009) Emerging PEGylated drugs Expert Opin. Emerg. Drugs 14 (2) 363-380
40. Myszka, D. G. (1999) Improving biosensor analysis J. Mol. Recognit. 12, 279-284
41. Wang, Y., Fei, D., Vanderlaan, M., and Song, A. (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro Angiogenesis 7 (4) 335-345
42. Wang, B., Pearson, T., Manning, G., and Donnelly, R. (2010) In vitro study of thrombin on tubule formation and regulators of angiogenesis Clin. Appl. Thromb-Hem. 16 (6) 674-678
43. Fuh, G., Wei-Ching, P. W., Mark, L., Chingwei, U., Moffat, V. L., and Wiesmann, C. (2006) Structure-function studies of two synthetic anti-vascular endothelial growth factor fabs and comparison with the Avastin Fab J. Biol. Chem. 281 (10) 6625-6631
44. Karlsson, R., Hakan Roos, R., Fagerstam, L., and Persson, B. (1994) Kinetic and concentration analysis using BIA technology Methods 6, 99-110
45. Schuck, P. (1997) Reliable determination of binding affinity and kinetics using surface plasmon resonance biosensors Curr. Opin. Biotechnol. 8, 498
46. Myszka, D. G. (1997) Kinetic analysis of macro molecular interactions using surface plasmon resonance biosensors Curr. Opin. Biotechnol. 8, 50-57
47. Chen, Y., Weismann, C., Fun, G., Li, B., Christinger, H. W., Mckay, P., M. De Vos, A., and Lowman, H. B. (1999) Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen J. Mol. Biol. 293, 865-881
48. Lowe, J., Araujo, J., Yang, J., Reich, M., Oldendorp, A., Shiu, V., Quarmby, V., Lowman, H., Lien, S., Gaudreault, J., and Maia, M. (2007) Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo Exp. Eye Res. 85 (4) 425-430
49. Nisonoff, A. and Rivers, M. M. (1961) Recombination of a mixture of univalent antibody fragments of different specificity Arch. Biochem. Biophys. 93, 460-462
50. 2 antibody containg thioether-linked Fab' fragments J Immunol. 139 (7) 2367-2375
51. Brennen, M. (1985) Preparation of bispecific antibodies by chemical recombinant of monoclonal immunoglobulin G1 fragments Science 229 (4708) 81-83
52. Doppalapudi, V. R., Huang, J., Liu, D., Jin, P., Liu, B., Li, L., Desharnais, J., Hagen, C., Levin, N. J., Shields, M. J., Parish, M., Murphy, R. E., Del Rosario, J., Oates, B. D., Lai, J. Y., Matin, M. J., Ainekulu, Z., Bhat, A., Bradshaw, C. W., Woodnutt, G., Lerner, R. A., and Lappe, R. W. (2010) Chemical generation of bispecific antibodies Proc. Natl. Acad. Sci. U.S.A. 107 (52) 22611-22616
53. Xiao, J., B. S. Hamilton, B. S., and Tolbert, T. J. (2010) Synthetic of N-terminally linked protein and peptide dimers by native chemical ligation Bioconjugate Chem. 21, 1943-1947
54. Cao, Y. and Lam, L. (2003) Bispecific antibody conjugates in therapeutics Adv. Drug Delivery Rev. 55 (2) 171-197
55. Van Assche, G. and Rutgeerts, P. (2000) Anti-TNF agents in Crohn's disease Expert Opin. Invest. Drugs 9 (1) 103-111
56. Stewart, M. W., Rosenfeld, P. J., Penha, F. M., Wang, F., Yehoshua, Z., Bueno-Lopez, E., and Lopez, P. F. (2012) Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor trap-eye) Retina 32 (3) 434
57. Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., and Yamaguchi, T. (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: A comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR J. Immunol. 184 (4) 1968-76
58. Korhonen, R. and Moilanen, E. (2009) Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis Basic Clin. Pharmacol. Toxicol. 104 (4) 276-84
59. Molineux, G. (2011) The development of romiplostim for patients with immune thrombocytopenia Ann. N.Y. Acad. Sci. 1222, 55-63
60. Chang, C.-H., Gupta, P., and Goldenberg, D. M. (2009) Advances and challenges in developing cytokine fusion proteins as improved therapeutics Expert Opin. Drug Discovery 4 (2) 181-194
61. Cordes, A. A., Platt, C. W., Carpenter, J. F., and Randolph, T. W. (2012) Selective domain stabilization as a strategy to reduce fusion protein aggregation J. Pharm. Sci. 101 (4) 1400-1409
62. Wriggers, W., Chakravarty, S., and Jennings, P. A. (2005) Control of protein functional dynamics by peptide linkers Biopolymers 80 (6) 736-746
63. Lengyel, J. S., Stott, K. M., Wu, X., Brooks, B. R., Balbo, A., Schuck, P., Perham, R. N., Subramaniam, S., and Milne, J. L. S. (2008) Extended polypeptide linkers establish the spatial architecture of a pyruvate dehydrogenase multienzyme complex Structure 16 (1) 93-103
64. Ma, B., Tsai, C.-J., HalilogÌlu, T., and Nussinov, R. (2011) Dynamic allostery: Linkers are not merely flexible Structure 19 (7) 907-917
65. Gustavsson, M., Lehtiö, J., Denman, S., Teeri, T. T., Hult, K., and Martinelle, M. (2001) Stable linker peptides for a cellulose-binding domain-lipase fusion protein expressed in Pichia pastoris Protein Eng. 14 (9) 711-715
66. Arai, R., Ueda, H., Kitayama, A., Kamiya, N., and Nagamune, T. (2001) Design of the linkers which effectively separate domains of a bifunctional fusion protein Protein Eng. 14 (8) 529-532
67. Le Gall, F., Reusch, U., Little, M., and Kipriyanov, S. M. (2004) Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody Protein Eng. Des. Sel. 17 (4) 357-366
68. Fang, M. (2003) Effects of interlinker sequences on the biological properties of bispecific single-chain antibodies Chin. Sci. Bull. 48 (21) 2277
69. Zhang, J., Yun, J., Shang, Z., Zhang, X., and Pan, B. (2009) Design and optimization of a linker for fusion protein construction Prog. Nat. Sci. 19 (10) 1197-1200
70. Chen, X., Lee, H. F., Zaro, J. L., and Shen, W. C. (2011) Effects of receptor binding on plasma half-life of bifunctional transferrin fusion proteins Mol. Pharmaceutics 8 (2) 457-465
71. Weatherill, E. E., Cain, K. L., Heywood, S. P., Compson, J. E., Heads, J. T., Adams, R., and Humphreys, D. P. (2012) Towards a universal disulphide stabilised single chain Fv format: Importance of interchain disulphide bond location and vL-vH orientation Protein Eng. Des. Sel. 25 (7) 321-329
72. Kufer, P., Lutterbuse, R., and Baeuerle, P. A. (2004) A revival of bispecific antibodies Trends Biotechnol. 22 (5) 238-244
73. Asano, R., Nakayama, M., Kawaguchi, H., Kubota, T., Nakanishi, T., Umetsu, M., Hayashi, H., Katayose, Y., Unno, M., Kudo, T., and Kumagai, I. (2011) Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system FEBS J. 279 (2) 223-233
74. Pasche, N. and Neri, D. (2012) Immunocytokines: A novel class of potent armed antibodies Drug Discovery Today 17 (11-12) 583-590
75. Kontemann, R. (2012) Dual targeting strategies with bispecific antibodies mAbs 4 (2) 182-197
76. Fischer, N. and Leger, O. (2007) Bispecific antibodies: Molecules that enable novel therapeutic strategies Pathobiology 74 (1) 3-14
77. Strop, P., Ho, W.-H., Boustany, L. M., Abdiche, Y. N., Lindquist, K. C., Farias, S. E., Rickert, M., Appah, C. T., Pascua, E., Radcliffe, T., Sutton, J., Chaparro-Riggers, J., Chen, W., Casas, M. G., Chin, S. M., Wong, O. K., Liu, S.-H., Vergara, G., Shelton, D., Rajpal, A., and Pons, J. (2012) Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair J. Mol. Biol. 420 (3) 204-219
78. Wurch, T., Pierré, A., and Depil, S. (2012) Novel protein scaffolds as emerging therapeutic proteins: From discovery to clinical proof-of-concept Trends Biotechnol. 30 (11) 575-582
79. Huang, C.-J., Lin, H., and Yang, X. (2012) Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements J. Ind. Microbiol. Biotechnol. 39 (3) 383-399
80. Kramer, R. H. and Karpen, J. W. (1998) Spanning binding sites on allosteric proteins with polymer-linked ligand dimers Nature 395 (6703) 710-713
81. Shan, M., Bujotzek, A., Abendroth, F., Wellner, A., Gust, R., Seitz, O., Weber, M., and Haag, R. (2011) Conformational analysis of bivalent estrogen receptor ligands: From intramolecular to intermolecular binding ChemBioChem 12 (17) 2587-2598
82. 3 receptors Bioconjugate Chem. 15 (2) 278-289
83. Das, R., Baird, E., Allen, S., Baird, B., Holowka, D., and Goldstein, B. (2008) Binding mechanisms of PEGylated ligands reveal multiple effects of the PEG scaffold Biochemistry 47 (3) 1017-1030
84. Stefano, J. E., Bird, J., Kyazike, J., Cheng, A. W.-M., Boudanova, E., Dwyer, M., Hou, L., Qiu, H., Matthews, G., O'callaghan, M., and Pan, C. Q. (2012) High-affinity VEGF antagonists by oligomerization of a minimal sequence VEGF-binding domain Bioconjugate Chem. 23 (12) 2354-2364
85. Albrecht, H., Denardo, G. L., and Denardo, S. J. (2007) Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers Q. J. Nucl. Med. Mol. Imaging 51 (4) 304-313
86. Lo Verso, F. and Likos, C. N. (2008) End-functionalized polymers: Versatile building blocks for soft materials Polymer 49 (6) 1425-1434
87. Semenov, A. N., Joanny, J. F., and Khokhlov, A. R. (1995) Associating polymers: Equilibrium and linear viscoelasticity Macromolecules 28 (4) 1066-1075
88. Elli, S., Eusebio, L., Gronchi, P., Ganazzoli, F., and Goisis, M. (2010) Modeling the adsorption behavior of linear end-functionalized poly(ethylene glycol) on an ionic substrate by a coarse-grained Monte Carlo approach Langmuir 26 (20) 15814-15823
89. Fee, C. and Van Alstine, J. (2004) Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins Bioconjugate Chem. 15 (6) 1304-1313
90. Lu, Y., Harding, S. E., Turner, A., Smith, B., and Athwal, D. S. (2008) Effect of PEGylation on the solution conformation of antibody fragments J. Pharm. Sci. 97 (6) 2062-2079
91. Thielges, M. C., Zimmermann, J. R., Yu, W., Oda, M., and Romesberg, F. E. (2008) Exploring the energy landscape of antibody-antigen complexes: Protein dynamics, flexibility, and molecular recognition Biochemistry 47 (27) 7237-7247
92. Kubetzko, S., Sarkar, C. A., and Plückthun, A. (2005) Protein PEGylation decreases observed target association rates via a dual blocking mechanism Mol. Pharmacol. 68 (5) 1439-1454
93. Mabry, R., Rani, M., Geiger, R., Hubbard, G. B., Carrion, R., Brasky, K., Patterson, J. L., Georgiou, G., and Iverson, B. L. (2005) Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region Infect. Immun. 73 (12) 8362-8368
94. Bostrom, J., Yu, S.-F., Kan, D., Appleton, B. A., Lee, C. V., Billeci, K., Man, W., Peale, F., Ross, S., Wiesmann, C., and Fuh, G. (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site Science 323 (5921) 1610-1614
95. Vauquelin, G. and Charlton, S. J. (2010) Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action Br. J. Pharmacol. 161 (3) 488-508
96. Kane, R. S. (2010) Thermodynamics of multivalent interactions: Influence of the linker Langmuir 26 (11) 8636-8640
97. Krishnamurthy, V. M., Semetey, V., Bracher, P. J., Shen, N., and Whitesides, G. M. (2007) Dependence of effective molarity on linker length for an intramolecular protein-ligand system J. Am. Chem. Soc. 129 (5) 1312-1320
98. Jencks, W. P. (1981) On the attribution and additivity of binding energies Proc. Natl. Acad. Sci. U.S.A. 78 (7) 4046-4050
99. Vauquelin, G. and Charlton, S. J. (2013) Exploring avidity: Understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands Br. J. Pharmacol. 168 (8) 1771-1785
100. Copeland, R. A. (2011) Conformational adaptation in drug-target interactions and residence time Future Med. Chem. 3 (12) 1491-1501
101. Yin, N., Pei, J., and Lai, L. (2013) A comprehensive analysis of the influence of drug binding kinetics on drug action at molecular and systems levels Mol. BioSyst. 9 (6) 1381-1389
102. Mack, E. T., Snyder, P. W., Perez-Castillejos, R., Bilgiçer, B., Moustakas, D. T., Butte, M. J., and Whitesides, G. M. (2012) Dependence of avidity on linker length for a bivalent ligand-bivalent receptor model system J. Am. Chem. Soc. 134 (1) 333-345
103. Shewmake, T. A., Solis, F. J., Gillies, R. J., and Caplan, M. R. (2008) Effects of linker length and flexibility on multivalent targeting Biomacromolecules 9 (11) 3057-3064
104. Cojocariu, G. and Natansohn, A. (2002) Intramolecular complexation in aqueous solutions of an end-capped poly(ethylene glycol) J. Phys. Chem. B 106 (45) 11737-11745
105. Numata, J., Juneja, A., Diestler, D. J., and Knapp, E. W. (2012) Influence of spacer-receptor interactions on the stability of bivalent ligand-receptor complexes J. Phys. Chem. B 116 (8) 2595-2604
106. Rodríguez-Martínez, J., Solá, R., Castillo, B., Cintrón-Colón, H., Rivera-Rivera, I., Barletta, G., and Griebenow, K. (2008) Stabilization of α-chymotrypsin upon PEGylation correlates with reduced structural dynamics Biotechnol. Bioeng. 101 (6) 1142-1149
107. Gonnelli, M. and Strambini, G. B. (2009) No effect of covalently linked poly (ethylene glycol) chains on protein internal dynamics BBA-Proteins and Proteomics 1794, 569-576
108. Weber, M., Bujotzek, A., and Haag, R. (2012) Quantifying the rebinding effect in multivalent chemical ligand-receptor systems J. Chem. Phys. 137 (5) 054111